Home > Request Information
Title:
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study
* Company:
* Country:
* Name:
Job Title:
* Tel:
Fax:
* E-mail:
Message:
Verification Code:
refresh